Find Elapegademase manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Revcovi, Elapegademase-lvlr, Elapegademase [inn], Unii-9r3d3y0uhs, Elapegademase [usan:inn], 9r3d3y0uhs
Molecular Formula
C10H20N2O5
Molecular Weight
248.28  g/mol
InChI Key
XNGDIOBPVDBNQH-QMMMGPOBSA-N

Elapegademase
Elapegademase is a recombinant form of the enzyme adenosine deaminase (rADA), based on the bovine amino acid sequence and covalently conjugated, with a succinimidyl carbamate linker, to monomethoxypolyethylene glycol (mPEG) (SC-PEG rADA), that can be used as an enzyme replacement agent for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID). Upon intramuscular administration, elapegademase, as an exogenous source of ADA, replaces the deficient ADA enzyme and acts in the same manner as the endogenous enzyme. ADA is involved in purine metabolism and mainly catalyzes the irreversible hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively, as well as several naturally occurring methylated adenosine compounds. Elapegademase decreases toxic levels of adenosine and deoxyadenosine nucleotides, increases lymphocyte levels and helps maintain the proper functioning of immune cells. Elevated adenosine levels, as seen in ADA deficiency, induce apoptosis and inhibit the differentiation of thymocytes, resulting in T-lymphopenia. Low levels of deoxyadenosine and adenosine play key roles in the regulation of lymphocyte levels and the proper functioning of immune cells.
1 2D Structure

Elapegademase

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-amino-6-(2-methoxyethoxycarbonylamino)hexanoic acid
2.1.2 InChI
InChI=1S/C10H20N2O5/c1-16-6-7-17-10(15)12-5-3-2-4-8(11)9(13)14/h8H,2-7,11H2,1H3,(H,12,15)(H,13,14)/t8-/m0/s1
2.1.3 InChI Key
XNGDIOBPVDBNQH-QMMMGPOBSA-N
2.1.4 Canonical SMILES
COCCOC(=O)NCCCCC(C(=O)O)N
2.1.5 Isomeric SMILES
COCCOC(=O)NCCCC[C@@H](C(=O)O)N
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Elapegademase-lvlr

2. Revcovi

2.2.2 Depositor-Supplied Synonyms

1. Revcovi

2. Elapegademase-lvlr

3. Elapegademase [inn]

4. Unii-9r3d3y0uhs

5. Elapegademase [usan:inn]

6. 9r3d3y0uhs

7. Schembl20670726

8. Ezn-2279

9. Q27272923

10. 1709806-75-6

11. Poly(oxy-1,2-ethanediyl), Alpha-carboxy-omega-methoxy-, Amide With Adenosine Deaminase (synthetic)

2.3 Create Date
2016-08-16
3 Chemical and Physical Properties
Molecular Weight 248.28 g/mol
Molecular Formula C10H20N2O5
XLogP3-2.7
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count10
Exact Mass248.13722174 g/mol
Monoisotopic Mass248.13722174 g/mol
Topological Polar Surface Area111 Ų
Heavy Atom Count17
Formal Charge0
Complexity235
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Elapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. This condition was previously treated by the use of bovine pegamedase as part of an enzyme replacement therapy. ADA-SCID is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme. The patients suffering from this disease often present with a compromised immune system. This condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infections.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

In clinical trials, elapegademase was shown to increase adenosine deaminase activity while reducing the concentrations of toxic metabolites which are the hallmark of ADA-SCID. As well, it was shown to improve the total lymphocyte count.


5.2 MeSH Pharmacological Classification

Adenosine Deaminase Inhibitors

Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)


5.3 ATC Code

L - Antineoplastic and immunomodulating agents

L03 - Immunostimulants

L03A - Immunostimulants

L03AX - Other immunostimulants

L03AX21 - Elapegademase


5.4 Absorption, Distribution and Excretion

Absorption

Elapegademase is administered intramuscularly and the reported Tmax, Cmax and AUC are approximately 60 hours, 240 mmol.h/L and 33000 hr.mmol/L as reported during a week.


Route of Elimination

This pharmacokinetic property has not been fully studied.


Volume of Distribution

This pharmacokinetic property has not been fully studied.


Clearance

This pharmacokinetic property has not been fully studied.


5.5 Metabolism/Metabolites

Metabolism studies have not been performed but it is thought to be degraded by proteases to small peptides and individual amino acids.


5.6 Biological Half-Life

This pharmacokinetic property has not been fully studied.


5.7 Mechanism of Action

The ADA-SCID is caused by the presence of mutations in the ADA gene which is responsible for the synthesis of adenosine deaminase. This enzyme is found throughout the body but it is mainly active in lymphocytes. The normal function of adenosine deaminase is to eliminate deoxyadenosine, created when DNA is degraded, by converting it into deoxyinosine. This degradation process is very important as deoxyadenosine is cytotoxic, especially for lymphocytes. Immature lymphocytes are particularly vulnerable as deoxyadenosine kills them before maturation making them unable to produce their immune function. Therefore, based on the causes of ADA-SCID, elapegademase works by supplementing the levels of adenosine deaminase. Being a recombinant and an _E. coli_-produced molecule, the use of this drug eliminates the need to source the enzyme from animals, as it was previously.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty